CO2019007298A2 - Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos - Google Patents

Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos

Info

Publication number
CO2019007298A2
CO2019007298A2 CONC2019/0007298A CO2019007298A CO2019007298A2 CO 2019007298 A2 CO2019007298 A2 CO 2019007298A2 CO 2019007298 A CO2019007298 A CO 2019007298A CO 2019007298 A2 CO2019007298 A2 CO 2019007298A2
Authority
CO
Colombia
Prior art keywords
isoform
context
inhibitors
permissive
tgfβ1
Prior art date
Application number
CONC2019/0007298A
Other languages
English (en)
Inventor
Thomas Schurpf
Abhishek Datta
Gregory J Carven
Constance Martin
Ashish Kalra
Kimberly Long
Alan Buckler
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of CO2019007298A2 publication Critical patent/CO2019007298A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

En el presente documento se describe el uso terapéutico de inhibidores de TGFβ1 isoforma-específicos, contexto-permisivos, en el tratamiento de enfermedades que implican la desregulación de TGFβ1.
CONC2019/0007298A 2017-01-06 2019-07-08 Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos CO2019007298A2 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US201762588626P 2017-11-20 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Publications (1)

Publication Number Publication Date
CO2019007298A2 true CO2019007298A2 (es) 2019-07-31

Family

ID=61198888

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007298A CO2019007298A2 (es) 2017-01-06 2019-07-08 Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos

Country Status (17)

Country Link
US (3) US20180207267A1 (es)
EP (1) EP3551658A1 (es)
JP (2) JP7157744B2 (es)
KR (1) KR20190098255A (es)
CN (2) CN110382530A (es)
AU (1) AU2018205231A1 (es)
BR (1) BR112019013908A2 (es)
CA (1) CA3049005A1 (es)
CL (1) CL2019001874A1 (es)
CO (1) CO2019007298A2 (es)
CR (1) CR20190350A (es)
DO (1) DOP2019000180A (es)
IL (2) IL267790A (es)
MX (1) MX2019008197A (es)
PE (1) PE20191661A1 (es)
PH (1) PH12019501575A1 (es)
WO (1) WO2018129329A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180122397A (ko) 2016-03-11 2018-11-12 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US20210122814A1 (en) 2018-07-11 2021-04-29 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
JP2022524281A (ja) * 2019-01-30 2022-05-02 スカラー ロック インコーポレイテッド ＴＧＦβのＬＴＢＰ複合体特異的阻害剤およびその使用
US20220170940A1 (en) 2019-03-27 2022-06-02 Singapore Health Services Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
WO2020206055A1 (en) * 2019-04-02 2020-10-08 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
TW202142571A (zh) 2019-08-28 2021-11-16 日商中外製藥股份有限公司 跨物種抗潛伏性TGF-β1抗體及使用方法
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 ***氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
CN115190812A (zh) 2020-01-11 2022-10-14 供石公司 TGFβ抑制剂及其用途
EP4087659A2 (en) 2020-01-11 2022-11-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
JP2024517016A (ja) 2021-05-11 2024-04-18 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
EP4337654A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR102628959B1 (ko) 2022-03-22 2024-01-24 오토텔릭바이오 주식회사 티아졸 유도체 화합물 및 이의 용도

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK1820858T3 (da) 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP2386575A3 (en) 2000-06-29 2011-11-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
GB0230202D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
BRPI0607639B1 (pt) 2005-02-08 2022-04-05 Genzyme Corporation Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica
SI2125894T1 (sl) * 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011102483A1 (ja) 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
CN103596591B (zh) * 2011-02-08 2016-08-24 Abbvie公司 骨关节炎和疼痛的治疗
ES2894398T3 (es) * 2011-06-03 2022-02-14 Xoma Technology Ltd Anticuerpos específicos para TGF-beta
AU2012335247A1 (en) * 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
CA2855822C (en) 2011-11-14 2022-11-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
US9518112B2 (en) * 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
RS61778B1 (sr) * 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
KR20180122397A (ko) 2016-03-11 2018-11-12 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도

Also Published As

Publication number Publication date
US20180207267A1 (en) 2018-07-26
MX2019008197A (es) 2019-09-11
PH12019501575A1 (en) 2019-11-04
JP7157744B2 (ja) 2022-10-20
JP2020503362A (ja) 2020-01-30
KR20190098255A (ko) 2019-08-21
BR112019013908A2 (pt) 2020-02-04
WO2018129329A1 (en) 2018-07-12
US20240016928A1 (en) 2024-01-18
EP3551658A1 (en) 2019-10-16
IL267790A (en) 2019-09-26
CR20190350A (es) 2019-11-15
CA3049005A1 (en) 2018-07-12
US20190209682A1 (en) 2019-07-11
CN117398457A (zh) 2024-01-16
CL2019001874A1 (es) 2019-12-06
AU2018205231A1 (en) 2019-07-18
DOP2019000180A (es) 2019-09-15
JP2022188226A (ja) 2022-12-20
IL304416A (en) 2023-09-01
PE20191661A1 (es) 2019-11-11
CN110382530A (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
ECSP15026557A (es) Compuestos y sus métodos de empleo
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112018000254A2 (pt) inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2020003202A1 (es) Piridinil y pirazinil-(aza)indolsulfonamidas
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
CL2018003417A1 (es) Nuevos compuestos.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
UY38352A (es) Inhibidores de integrina alfavbeta6